For speed, scale, and reliability sourcing PBMCs, choose Discovery.
Accelerate your precision oncology program with Discovery’s extensive inventory and prospective network for PBMCs.
PERIPHERAL BLOOD MONONUCLEAR CELLS
- Diseased blood is collected just prior to the patient’s next cycle of therapy (typically, a 2-4 week washout period) at standard laboratory appointments as dictated by the patient’s oncologist.
- PBMCs are frozen in 90% heat-inactivated FBS +10% DMSO and use sodium heparin as an anticoagulant.
- The final product volume is 1.0 mL
- Cell counts typically range from 5M to 10M cells per million
- After thawing, cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer. In our experience, this offers more accurate cell counts and viabilities of this product than using trypan blue or any other method of counting. We strongly recommend against using flow cytometry or any other counting method as they can artificially decrease cell counts and viabilities.
PBMC Matched Sets
Our Discovery Partners® network allows for large-scale, prospective collections of high-quality matched sample sets of human biospecimens. Each matched sample set is provided with the base clinical data from the patient case, along with redacted pathology information.
- BMMCS + PBMCs Matched Sets
- DTCs + PBMCs – including cell population analysis of DTCs by flow cytometry
- DTCs + PBMCs + FFPE – including cell population analysis of DTCs by flow cytometry
PBMCs Technical Resources
Checkpoint inhibitor therapy utilization and PD1/PDL1 expression across a global clinical network.
Peripheral Blood Mononuclear Cells
A quick reference resource for scientists who need to isolate, manipulate, or develop assays involving human mononuclear cells.
Standard processing of diseased peripheral blood mononuclear cells (PBMCs).
Need Biomarker Characterization For Your Human Cancer Biospecimens?
While our biospecimens are highly characterized, we also provide streamlined multi-omic biomarker analyses to further characterize biospecimens from our inventory or from your studies via our global CLIA / CAP service laboratories*.
- HudsonAlpha Discovery
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeting Panels
- Hi-Fi Long Read Sequencing
- RNA Sequencing
- Single Cell Sequencing
- Multiplexed IF (mIF)
- RNA Scope
- Digital Pathology & Image Analysis
- In-Situ Hybridization
- Flow Cytometry
- Dissociation & Isolation
- Cell Culture & Expansion
*HudsonAlpha Discovery Sequencing and Bioinformatics laboratory is CLIA registered, pending CAP accreditation.
Frequently Asked Questions
How are your PBMCs processed?
You can find our PBMCs Protocols by clicking here.
We also have the ability to follow our clients’ custom processing protocols and help them develop new processing protocols based on their needs.
What is your Standard Collection Tube for PBMCs?
What are your Storage and Shipping Temperature guidelines for PMBCs?
Are red blood cells lysed prior to cryopreservation?
How are cell counts and viabilities of PBMCs determined?
What is the difference between PBMCs and MNCs?
What anticoagulant is used for PBMCs?
Are blast percentages available for diseased PBMC and BMMC samples?
How is post thaw QC performed for PBMCs?
Following at least 24 hours in liquid nitrogen, one vial is removed from storage and quickly thawed in a 37°C water bath until only a small frozen crystal remains. Vials are transferred into a biosafety cabinet and diluted with an appropriate volume of DMEM/F12 + 10% FBS in a 15ml conical tube to ensure linearity with the Nexcelom Cellometer. 20µl of the cell suspension is mixed with 20µl of acridine orange/propidium iodide and counted on the Nexcelom Cellometer to determine cell counts and viability. All cell counts are performed prior to any pelleting and washing of the samples. These counts are estimations of the total live cell yield.
How are PBMCs cryopreserved?
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!